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Abstract Evidence-performance-gaps between 
guidelines and treatment of type 2 diabetes (T2DM) 
in daily practice have been reported, especially in 
primary care. We aimed to assess the potential gap 
comparing current treatment in primary care with 
guidelines and patients’ characteristics from large 
clinical trials that guidelines are based on, namely 
UKPDS, ACCCORD, ADVANCE, STENO-2 and 
VADT. Methods: We undertook a cross-sectional 
study and extracted data on 541 patients with 
T2DM from a clinical information system of a GP 
network in Switzerland. Results: Our study 
population was comparable to patients in 
ACCORD, ADVANCE and VADT at baseline. 
Patients in UKPDS and STENO-2 differed in age 
and disease duration. HbA1c-levels (7.3%), LDL-
level (2.6 mmol/l), systolic and diastolic (135/78 
mmHg) blood pressure were lower in our study 
than in the reference studies. 39.4% received an 
ACE-inhibitor, 41.6% statins and 41.4% aspirin. 
Conclusion: Taking into consideration the results of 
recent large clinical trials indicating that very strict 
treatment goals are of no additional benefit, most 
patients in Swiss primary care would not benefit 
from a treatment intensification regarding HbA1c, 
blood pressure and cholesterol targets. Evidence-
performance-gaps were observed mainly 
concerning the choice of first line medication.  
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1. Introduction  
 
Guidelines and treatment recommendations are 
usually based on the results of large clinical trials. 
Regarding the treatment of cardiovascular risk 
factors in patients with type 2 diabetes (T2DM), the 
guideline of the European Society of Cardiology 
(ESC) and the European Association for the Study of 
Diabetes [1-3] target values for glycated 
haemoglobin (HbA1c), lipid-levels, blood-pressure 
and gives recommendations for ideal weight as well 
as pharmacotherapy. This guideline is accepted as a 
standard for clinical practice in Europe as well as in 
Switzerland. The latest version of these guidelines 
[2] recommends rather moderate target values and 
emphasizes the necessity of individualized 
treatment plans, taking into account age, duration of 
T2DM, history of cardiovascular disease (CVD) and 
other comorbidities. However, in the past, the 
recommended target values were very strict. Many 
studies have revealed a substantial gap between 
guidelines and treatment (evidence-performance-
gap) in daily practice, especially in primary care [4-
6]. One approach for explaining this evidence-
performance-gap is to assume substantial 
differences between the patients included in the 
large – mostly pharmaceutical – randomized 
controlled trials (RCTs) and the patients seen by 
general practitioners (GP) in daily practice. This 
approach is supported by a study of Boyd et al. 
outlining that 40% of clinical trials on diabetes 
excluded patients with comorbidities such as 
cardiovascular disease and 17% excluded patients 
aged >65 years [7]. Lacking guideline-adherence 
would be a consequence of the GPs’ adaption of the 
target values to their “real life patients” and the 
individualization of treatment plans balancing 
benefits of stringent goals and their potential harms 
for patients of higher age, with multimorbid 
conditions or proneness to hypoglycaemia. An 
exploration of this hypothesis could be undertaken 
on the basis of a structured comparison between a 
population of GP patients with T2DM and the study 
populations of large clinical RCTs that contributed 
to the specification of target values. In this context, a 
description of patients with T2DM treated in Swiss 
primary care could be of international value, 
because Switzerland is a good example of a western 
country with an insurance based health care system 
with a fee-for-service reimbursement and mostly 
free choice of doctors – a model that can also be 
found in other countries, e.g. Austria, France or 
Germany. However, both data on the characteristics 
and on metabolic and cardiovascular risk control in 
Swiss GP patients with T2DM are scarce. 
 
2. Objective  
 
The aim of this study is to gather information on 
patients with long-standing T2DM in Swiss primary 
care and to assess a possible performance gap in 
comparing current treatment with guidelines under 
consideration of differences between these real life 
patients to patients from large clinical trials, namely 
UKPDS [8], ACCCORD [9], ADVANCE [10], VADT 
[11] and STENO-2 [12].  
 
 3. Methods  
 
Data on patients with T2DM were prospectively 
collected in a GP network in the greater region of 
Zurich (Medix), Switzerland, using an internet 
based clinical information system (DataBox), which 
enables the registration of vital parameters, 
laboratory values, actual medication, as well as the 
early detection of diabetic complications. There was 
no special standardization in terms of data 
acquisition throughout the participating practices. 
GPs were asked to include all patients with T2DM 
consecutively as they appeared in the practice. 
Patients with newly diagnosed diabetes mellitus 
(less than 6 months) were excluded from the 
analysis due to the study aim of investigating only 
patients suffering from long-standing diabetes. The 
data presented in this study are from the last 
consultation of each patient during the period from 
January 2010 until April 2011.  
 
We assessed sociodemographic parameters (age, 
sex, duration of disease), glycemic control (HbA1c), 
cardiovascular risk factors (systolic and diastolic 
blood pressure (BP), Low Density Lipoprotein 
(LDL)-cholesterol concentration, smoking 
behaviour, Body Mass Index), multimorbidity 
(diagnosis of chronic illness in addition to T2DM) 
and medication from the structured entries in the 
DataBox database. 
Corresponding information about the study 
populations of UKPDS [8], ACCCORD [9], 
ADVANCE [10], VADT [11] and STENO-2 [12] were 
retrieved from the original publications by two 
independent investigators (SD, FM). We compared 
our data with the baseline characteristics of the 
above-mentioned large landmark studies. 
At the time that the study was conducted and 
patients in our study received care, the ESC/EASD 
guidelines of 2007 [1] were valid and defined target 
values for HbA1c, systolic and diastolic BP and 
LDL-cholesterol concentration. We measured our 
findings against these target values as well as 
against the target values proposed by the latest 
version of the guideline [2] and evaluated the 
potential evidence-performance gap. 
 
3.1 Statistical analysis  
 
Continuous variables are presented as means and 
standard deviations (SD), categorical data as 
frequencies and percentages. . Data were analysed 
using Microsoft Excel 2010 software (version 
14.0.6106.5005).  
 
4. Results 
 
Between January 2010 and April 2011 21 out of 92 
eligible network GPs collected data on a total of 541 
patients suffering from T2DM for more  than 6 
months. Patient characteristics are provided in table 
1.  
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Table 1. Patient characteristics according to study 
population and ESC/EASD guideline. Data are presented 
as mean values ± standard deviation if not otherwise 
declared (n.a = not available). 
 
4.1 Sociodemographic parameters 
 
Regarding the sociodemographic parameters the 
mean age of our study population was older (68±12 
years) than in UKPDS (53±9 years), ACCORD (62±7 
years), ADVANCE (66±6 years), STENO-2 (55±7 
years) and VADT (60±9 years). The proportion of 
female patients was 32% in our study, 39% in 
UKPDS, 39% in the ACCORD-study, 42% in the 
ADVANCE-trial and 26% in STENO-2. In the 
VADT-trial virtually all patients were male. The 
time since T2DM onset in our study was 10.3±7.8 
years, this was similar in the ACCORD-study (10 
years), while the duration of T2DM in the VADT-
trial (11.5±8 years) was longer. Duration of disease 
was shorter in ADVANCE (8±6 years) and STENO-2 
(6 years). The UKPDS-study only included patients 
with newly diagnosed type 2 diabetes.  
 
4.2 Glycemic control 
 
HbA1c was chosen as a surrogate for glycemic 
control. In our study population, HbA1c was 
7.3±1.2% in 530 analyzed patients which is 
comparable to the ADVANCE-trial (7.2±1.6%) but 
less than in ACCORD (8.3±1.1%), STENO-2 
(8.8±1.6%) and VADT 9.4±2.0%). HbA1c in the 
UKPDS-study was not directly comparable because 
patients had newly diagnosed T2DM. 
The ESC/EASD guideline of 2007 cites international 
diabetes associations, recommending a HbA1c 
target of ≤6.5% or <7% [1]. In 2013, the guideline 
recommends a target value of ≤7% with 
acknowledgement of individual requirements of the 
patient. For elderly people in whom lower targets 
cannot be achieved, a HbA1c level of 7.5–8% is 
recommended [2].  
 
4.3 Cardiovascular risk factors 
 
Cardiovascular risk factors in addition to T2DM 
were defined as arterial hypertension, dyslipidemia, 
overweight/obesity and smoking. We had no 
information on familiar predisposition. The 
proportion of patients with one, two or three 
additional cardiovascular risk factors was 46%, 29% 
and 3% respectively. T2DM was the single reported 
cardiovascular risk factor in 22% of patients. The 
mean age of patients with T2DM as the only 
cardiovascular risk factor was 69.6±12.3 years, 
similar to the mean age of the whole study 
population. 
Mean systolic BP in our study was 135±16 mmHg, 
which was similar to baseline measurements in 
UKPDS (135±20 mmHg), ACCORD (136±17 mmHg) 
and VADT (132±17 mmHg) and less than in 
ADVANCE (145±22 mmHg) and STENO-2 (149 
mmHg). Mean diastolic BP was 78±10 mmHg. Thus, 
it was lower than in UKPDS (82±10 mmHg), 
ADVANCE (81±11 mmHg) and STENO-2 (86 
mmHg) but higher than in ACCORD (75 mmHg) 
and VADT (76±10 mmHg).  
The ESC/EASD guideline of 2007 [1] recommends a 
target value of <130/80 mmHg. Consequently, the 
prevalence of hypertensive BP in our study 
population was 73% (452 of 541 patients analyzed). 
Considering the less stringent BP goals of the 
current guideline (<140/85 mmHg) [2] still 44.5% of 
our patients did not meet the criteria.  
Laboratory data on lipid-concentrations were 
obtained in 350 out of 541 patients. The mean LDL 
level was 2.6±1.0 mmol/l and thus lower than in all 
landmark studies (table 1). 
Both ESC/EASD guidelines of 2007 and 2011 
recommend a LDL-cholesterol target value of <1.8 
mmol/l for patients at very high cardiovascular risk 
(documented or severe CVD, or ≥1 cardiovascular 
risk factor in addition to T2DM and/or target organ 
damage) and <2.5 mmol/l for patients with high 
cardiovascular risk (no cardiovascular risk factor in 
addition to T2DM and free of target organ damage) 
[1, 2]. In our study, 77% of the patients had a LDL 
level of ≥1.8 mmol/l and 53% had a LDL level >2.5 
mmol/l.  
Overweight, defined as a BMI of 25 kg/m2 or more, 
was prevalent in 82% of our study population. The 
prevalence of obesity defined as a BMI of 30 kg/m2 
or more was 42% in our study (400 of 541 patients 
analyzed). Although the mean BMI of our study 
population (29±5 kg/m2) was higher than in the 
UKPDS-trial (28±5 kg/m2) and ADVANCE-trial 
(28±5 kg/m2), it was lower than in ACCORD (32±6 
kg/m2), STENO-2 (31 kg/m2) and VADT (31±4 
kg/m2).   
Treatment goals according to the ESC/EASD 
guideline are defined as BMI<25 kg/m2. The latest 
guideline drops specific thresholds and suggests 
weight stabilization based on calorie balance as a 
goal. 
The proportion of current smokers was 7%, the 
lowest in our study compared to the landmark 
trials. The UKPDS-trial reported 30% current 
smokers, the ACCORD- and ADVANCE-trial 
reported 14% current smokers each, while in the 
STENO-2-study there was a proportion of 38% 
current smokers and 17% in the VADT-trial.  
 
4.4 Multimorbidity 
 
In a subset of 350 patients information on 
multimorbidity was available.  
Multimorbidity, defined as at least one chronic 
condition (arterial hypertension, coronary heart 
disease, obesity, chronic obstructive lung disease, 
asthma, chronic renal insufficiency or depression) in 
addition to T2DM was prevalent in 81% of these 
patients. 13% of our study population had a history 
of coronary heart disease compared to 40% in 
VADT, 37.5% in STENO-2, 35% in ACCORD and 
32% in ADVANCE. UKPDS did not provide 
respective information. Availability of further data 
on comorbidity was varying across the reference 
trials and therefore was not directly comparable 
with our study. 
 
4.5 Medication  
 
Information on medication was available in all of 
the 541 patients. Only the ADVANCE-trial and the 
STENO-2-study provided similarly comprehensive 
data on medication use. An overview about the 
medication is provided in table 2.  
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Table 2. Medical treatment according to study population.  
Data are presented as % if not otherwise declared  
(n.a = not available). 
 
Metformin was the most prescribed antidiabetic 
drug in 58.6% of our patients. This was lower than 
in ADVANCE but higher than in STENO-2. 
Sulfonylurea was taken by 26.4% in our study, 
which was less than in both ADVANCE (63.5%) and 
STENO-2 (54.5%). Insulin was used by 16.1% of our 
patients, which was less often than in ACCORD 
(35.0%) and VADT (52.0%) but more than in 
ADVANCE (11.5%) and STENO-2 (10.0%). Both, the 
ESC/EASD guideline of 2007 and 2011 recommend 
metformin as first-line agent in patients with T2DM 
especially when overweight. 
39.4% patients of our study population received an 
angiotensin-converting-enzyme (ACE)-Inhibitor. 
This proportion was lower than in the ACCORD-
study. 54.2% of our patients took either an ACE-
Inhibitor and/or an angiotensin-II-receptor (ATII)-
antagonist, which was more than in the STENO-2-
trial (19.5%). 7.9% received other antihypertensive 
drugs. Both, the ESC/EASD guideline of 2007 and 
2011 recommend ACE-inhibitors as first-line 
antihypertensive drug in patients with T2DM. 
Aspirin was prescribed in 41.4% of cases in our 
study as compared to 44.0% in ADVANCE and 
14.0% in STENO-2. Both ESC/EASD guidelines 
recommend aspirin as secondary prevention in 
patients with T2DM but not as primary prevention. 
Statin use was only higher in the ACCORD-trial 
(59.3%) while statins were prescribed in 41.6% of 
our study population, 28.3% in ADVANCE and 
1.5% in STENO-2 respectively. 86 of 235 (37%) 
patients in our study population with an LDL-
cholesterol concentration of 1.8 mmol/l and higher 
were prescribed a statin, while 38 of 70 (54%) 
patients with a LDL concentration of less than 1.8 
mmol/l were taking a statin. Of those patients with a 
history of CVD, 35.7% received a statin. The 
ESC/EASD guidelines of 2007 recommend a statin 
therapy for all patients with T2DM but without 
CVD if the total cholesterol level is >3.5 mmol/l, 
whereas patients with T2DM and CVD should 
receive statins regardless of LDL or total cholesterol 
[1]. In contrast, the latest guidelines recommend 
statins in all patients with T2DM, only the treatment 
goal varies depending on the cardiovascular risk 
profile [2].  
 
5. Discussion  
 
In our study we analyzed the characteristics of 
patients with diabetes type 2 from general practices 
in the greater region of Zurich, Switzerland and 
compared them with baseline characteristics of the 
study populations from large landmark studies, 
namely UKPDS, ACCORD, ADVANCE, STENO-2 
and VADT.  
 
5.1 Differences between populations 
 
Our results show that our study population is 
comparable to the populations described in the 
landmark studies, namely ACCORD, ADVANCE 
and VADT, especially as far as age, duration of 
T2DM, BP, LDL-levels and BMI is concerned. The 
proportion of smokers varied widely among the 
different trials, being the smallest in our study. 
These differences are probably due to inconsistent 
data recording, therefore the prevalence was 
regarded as not directly comparable. Also, 
information on comorbidities was scarcely reported 
by the landmark studies and thus not directly 
comparable. However, it is to note, that the range of 
additional cardiovascular risk factors other than 
T2DM was greater in our study than reported by the 
other studies (1–4 factors vs. at least 1 factor). 
The study population in UKPDS was clearly 
younger, included only patients with newly 
diagnosed T2DM with lower HbA1c values, lower 
BMI and higher mean LDL. In the STENO-2-trial, 
besides a relatively young age at baseline, HbA1c, 
BP and LDL-levels were among the highest 
compared to the other studies. The difference in 
patient characteristics between our study 
population and the UKPDS and STENO-2-trial is 
explained by strict exclusion criteria in the process 
of patient recruitment in these studies. In contrast, 
our study population represents a real life setting 
since patients were included consecutively during 
daily consultations in general practice. To conclude, 
populations in ACCORD, ADVANCE and VADT 
were more similar to a real life population in Swiss 
primary care than the population in UKPDS and 
STENO-2. As a consequence, recommendations 
retrieved from these studies are more likely 
applicable to primary care than are 
recommendations retrieved from the latter studies. 
In spite of the comparability with ACCORD, 
ADVANCE and VADT at first sight, HbA1c, BP and 
LDL-concentration in our study were the lowest 
compared to the other trials at baseline. We explain 
this finding with the influence that these landmark 
studies generally had on physicians’ awareness on 
diabetes care and cardiovascular risks and led them 
to intensify their treatment on the one hand, but at a 
slower rate and with less aggressive goals than 
imposed by the ESC/EASD guidelines of 2007, valid 
at the time that the study was conducted. Thus, only 
a minority of patients in our study achieved the 
stringent target values of this guideline. 
 
5.2 Gaps in comparison to guidelines 
 
With respect to glucose control, the 2007 ESC/EASD 
guidelines for treating diabetes mainly rely on 
evidence from the UKPDS- and STENO-2 trial [1]. 
In both studies gaps between patient characteristics 
compared to our study were the largest. In the 
ACCORD-study, where patient characteristics were 
closer to our study population, an increased 
mortality with tight blood sugar control could be 
demonstrated [9, 13].  
Regarding BP, the stringent goals as proposed by 
the ESC/EASD guidelines 2007, are mainly based on 
the UKPDS-study [14] and the HOT-study [15]. Both 
studies show substantial differences with respect to 
baseline characteristics compared to our study 
population, especially age. Evidence for lowering 
BP below 130/80 mmHg in patients with T2DM 
comes mainly from the ACCORD BP-trial [16], the 
SANDS- [17] and the ABCD-trial [18]. While the 
ACCORD-BP-trial and the ABCD-trial showed a 
benefit of stringent BP control regarding stroke and 
progression of proteinuria, neither the ACCORD-
BP-trial nor the ABCD-trial or the SANDS-trial 
could show a benefit in reduction of coronary risk. 
Instead a common finding of all three studies was a 
rise in adverse events related to antihypertensive 
therapy.  
Regarding lipid lowering therapies current evidence 
shows a reduction of cardiovascular risk in 
secondary prevention with statins while reduction 
of mortality has been discussed more controversial 
[19-24]. None of the trials suggesting a benefit in 
primary prevention actually achieved mean LDL-
concentrations of less than 1.8 mmol/l. In one large 
metaanalysis subgroup analysis [25] showed a 
decreasing risk for cardiovascular events even 
below a LDL concentration of 1.8 mmol/l. So, the 
question arises where the optimal threshold for LDL 
concentration is. It must be acknowledged that 
lower LDL concentrations were usually achieved 
with a higher statin dose but also at the expense of a 
higher rate of stain related adverse effects. On the 
other hand, pleiotropic effects of statins potentially 
contribute to the reduced cardiovascular risk 
independently of the achieved LDL-concentrations. 
In the light of these uncertainties, the current 
guideline in the treatment of blood cholesterol to 
reduce atherosclerotic cardiovascular risk in adults 
released by the American Heart Association even 
refrains from making recommendations for specific 
LDL target values for primary or secondary 
prevention [26].  
Guidelines are based on the best available evidence 
and expert opinion. The underlying trials often 
concentrate only on one or a few parameters due to 
feasibility and study design. This often does not 
take in account the complex combinations of 
underlying disease in real life with multiple 
parameters affecting each other. As a result 
evidence on treating patients with multiple risk 
factors and multimorbid conditions is scarce [7].  
The ESC/EASD guideline 2007 tended to treat each 
cardiovascular risk factor separately and primarily 
focused on specific risk groups, not considering 
other important factors as age and sex. Additive 
effects of controlling different risk factors at the 
same time, as shown in UKPDS [14] and STENO-2 
[12] and considering sex, age and life expectancy 
may be more important than pursuing sharp 
treatment thresholds.  
Thus, the most recent recommendations for treating 
diabetes [2, 26, 27] are a welcome contribution to 
this discussion, since different goals for HbA1c are 
addressed to the specific needs of different age 
groups, taking in account even individual needs 
and preferences. When measuring the outcomes of 
the patients in our study against the latest, more 
moderate target values, the evidence-performance 
gap decreased, especially regarding glycemic 
control and BP. Regarding LDL, the evidence-
performance gap is actually not measurable 
anymore, because target levels are under discussion 
or even dropped. This finding substantiates the 
hypothesis that GPs in our study already adapted 
the guidelines to the needs of their patients before 
the guidelines have been officially revised. 
To conclude, our study population is well treated 
regarding HbA1c, BP and LDL-concentrations 
compared to current evidence. Nevertheless, there is 
still room for improvement left, especially in regard 
to medication regimen. 
 
5.3 Differences in medication use 
 
Medication use among patients in our study 
differed in many cases from the medication 
prescribed in the other trials and guideline 
recommendations. Despite most of our patients 
being overweight, only little more than half were 
prescribed metformin, while in ADVANCE 
metformin was used in considerably more patients 
at baseline. Similarly, only approximately one third 
of the patients in our study received ACE inhibitors 
to lower blood pressure, although prevalence of 
hypertension was higher. 
Similarly, statins were only used in less than half of 
our patients. Roughly a third of patients with a 
LDL-concentration above the treatment goal of less 
than 1.8 mmol/l were taking a statin. Interestingly in 
the ACCORD-trial, although four fifth of the study 
population was reported to take a statin at the end 
of follow up, the mean LDL-concentration was still 
clearly higher than the recommended threshold 
value by guidelines. 
According to guidelines we would have expected a 
much higher proportion of patients among our 
study population receiving the above mentioned 
medication. Reasons for this gap can only be 
assumed. Non-adherence of patients may play a 
role in not reaching treatment goals. It may be due 
to the fact that the effect of these medications can 
only be visualized partially (for example by 
laboratory data) while perception of long term 
effects on risk reduction in the individual patient 
remain vague. This may attenuate awareness of the 
importance of prescribing these medications by the 
treating physicians. Also fear of polypharmacy and 
side effects may hinder physicians and patients in 
the use of multiple substances. Concerns of the 
treating physician in doing more harm than good by 
administering the treatment regimen as proposed 
by the guidelines as well as patient concerns must 
be taken into account.  
 
5.4 Strength and limitations 
 
The strength of our study is certainly the use of 
clinical real life data from patients with T2DM in 
Swiss primary care, including not only data on 
glycemic control but also on other cardiovascular 
risk factors. So far, similar data on Swiss patients 
with T2DM were either retrieved from secondary 
care or focused on different hypotheses.  
For instance, Burgmann et al. have recently 
examined the metabolic control of Swiss patients 
with T2DM in light of international and national 
recommendations and concluded that metabolic 
control in these patients was less than optimal given 
a mean HbA1c of 7.7%, a hypertension rate of 80%, 
a mean LDL level of 2.6 mmol/l [28]. However, the 
study was a retrospective medical chart analysis of 
patients with T2DM admitted to a general internal 
medicine clinic. It is questionable if these data are 
qualified to represent Swiss primary care in general 
and not only a proportion of more urgent and 
severe cases that needed hospitalization.  
In contrast, Gerber et al. have gathered data from 
primary care by conducting a national cross-
sectional survey among 134 physicians and their 
patients in all four cultural regions of Switzerland 
[29]. The results point in the same direction as our 
results, demonstrating a bigger or smaller evidence-
performance depending on the guideline used as 
the state of the art (mean HbA1c 7.03±1.24%, mean 
systolic BP 138.5±16.6 mmHg, mean diastolic BP 
81.4±10.3 mmHg, mean LDL 2.8 mmol/l, mean BMI 
29.8). However it is to note, that the survey was 
primarily designed to detect local differences in the 
quality of diabetes care and to evaluate the role of 
different cultural backgrounds as predictor for the 
use and outcome of hyperglycemic medical therapy.  
In our study, we primarily aimed to assess the 
potential evidence-performance gap. Data were 
directly entered to the clinical information system 
by physicians during patients’ consultations and 
reflect clinical routine data from primary care. To 
our knowledge, it is the first time that such data 
have been available for analysis in Switzerland. 
It must be mentioned, however, that the lack of 
follow up in our study makes it impossible to 
compare glycemic and cardiovascular risk control as 
well as morbidity or mortality over time. Therefore, 
our results are limited to a cross-sectional view. It 
would be interesting to examine to what extent the 
recent publication of more moderate guidelines 
would influence the outcomes of primary care 
patients.  
It should be acknowledged that data acquisition 
was not standardized throughout our study 
practices apart from the structure inherent in the 
electronic clinical information system used to record 
the consultations. On the one hand, this could be 
considered to be a limitation; on the other hand, it is 
to note that we aimed to obtain real life data. 
Determining standards for a routine consultation of 
patients with T2DM would have influenced the 
usual patterns of physicians’ care and consequently 
unfold various effects on the physician-patient 
relation with unknown impact on patients’ 
compliance and – at last – outcomes. Thus, our 
results should be interpreted as results of 
unregulated diabetes care in a primary setting 
where the responsibility for care management rests 
primarily with the physician. As such they might be 
representative for comparable health care systems. 
 
6. Conclusion 
 
We conclude that patients with T2DM in Swiss 
primary care are comparable to patient populations 
of large landmark studies that highlighted the 
necessity of individual treatment plans and 
indicated that very strict treatment goals are of no 
additional benefit. As a consequence, most patients 
in Swiss primary care would not benefit from a 
treatment intensification regarding target values of 
HbA1c, BP and cholesterol. Apparently, current 
guidelines are more applicable to this patient 
population than earlier versions were, but an 
evidence-performance gap rests regarding the 
choice of first line medication. 
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Table 1. Patient characteristics according to study population and ESC/EASD guideline 2007. Data are presented as mean values ± standard deviation if not otherwise declared (n.a=not available).  
Baseline Characteristics Our study 
UKPDS 
1998 
ACCORD 
2008 
ADVANCE 
2008 
STENO-2 
1999 
VADT 
2009 
ESC/EASD 
guideline 2007 
Number of patients (n) 
541 
(32% women) 
3867 
(39% women) 
10251  
(39% women) 
11140  
(42% women) 
160  
(26% women) 1791  
Age (years) 68 ± 12 53 ± 9 62 ± 7 66 ± 6 55 ± 7 60 ± 9  
Duration of type 2 diabetes (years) 10.3 ± 7.8 <1 year 10 ± n.a. 8 ± 6 6  11.5 ± 8  
HbA1c (median %) 7.3 ± 1.2 7.1 ± 1.5 8.3 ± 1.1 7.2 ± 1.6 8.8 ± 1.6 9.4 ± 2.0 <6.5–7.0 
Systolic blood pressure ( mmHg ) 135 ± 16 135 ± 20 136 ± 17 145 ± 22 149  132 ± 17 < 130 
Diastolic blood pressure (mmHg) 78 ± 10 82 ± 10 75  81 ± 11 86  76 ± 10 < 80 
LDL-level (mmol/l) 2.6 ± 1.0 3.5 ± 1.1 2.7 ± 0.9 3.1 ± 1.0 3.4 2.8 ± 0.8 < 1.8 
Arterial Hypertension  
(prevalence %) 73% n.a.  n.a.  n.a.  
BMI (kg/m2 ) 29 ± 5 28 ± 5 32 ± 6 28 ± 5 31  31 ± 4 < 25 
Obesity (prevalence %) 42% n.a.  n.a.  n.a.  
Coronary heart disease  
(prevalence %) 
13% n.a. 35% 32% 37.5% 40%  
Current smoker (prevalence %) 7% 30% 14% 14% 38 % 17 %  
Multimorbidity  
[T2DM + at least 1 chronic condition]  
(prevalence %)  
81% n.a. n.a. n.a. n.a. n.a.  
Number of CVRF 1 to 4  at least 2 at least 1 at least 1 at least 1  
Target level of HbA1c in % in the 
intervention group   < 6.0 ≤ 6.5 ≤ 6.5 < 6.0  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Medical treatment according to study population. Data are presented as % if not otherwise declared (n.a=not available).  
Medication 
Our 
study  
UKPDS 
1998 
ACCORD 
2008 
ADVANCE 
2008 
STENO-2 
1999 
VADT 
2009 
Metformin 58.6 n.a.  71.4 16.0  
Glitazone 1.5 n.a.  3.7 0  
Sulfonylurea 26.4 n.a.  63.5 54.5  
Glinide 1.9 n.a.  1.7 n.a.  
Insulin 16.1 n.a. 35.0 11.5 10.0 52.0 
ACE-I 39.4 n.a. 52.9 n.a. 
19.5 
 
AT II-Antagonist 14.8 n.a.  n.a.  
Calcium-Antagonists 18.3 n.a.  n.a. 10.0  
Diureticum 30.1 14.0  n.a. 24.5  
BB 24.8 n.a. 29.2 n.a. 5.5  
Aspirin 41.4 n.a.  44 14.0  
Marcoumar 4.4 n.a.  n.a. n.a.  
Statin 41.6 n.a. 59.3 28.3 1.5  
Any antihypertensive drug 62.1 12.0 85.4 75.1 41.0  
Any lipid lowering drug 41.6 0.3  36.7   
